Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade D 171.485 1.76% 2.97
VRTX closed up 0.21 percent on Monday, April 22, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Apr 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical VRTX trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 1.76%
Calm After Storm Range Contraction 1.76%
NR7 Range Contraction 1.76%
Lower Bollinger Band Walk Weakness 1.76%
Inside Day Range Contraction 1.76%
Below Lower BB Weakness 1.76%
Lower Bollinger Band Touch Weakness 1.76%
Oversold Stochastic Weakness 1.76%
Hammer Candlestick Bullish 1.98%
Pocket Pivot Bullish Swing Setup 1.98%

Older signals for VRTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Chemistry Chemical Compounds Organic Compounds Infection Influenza Cystic Fibrosis Serious Diseases Cyclopropanes Autoimmune Disease Breakthrough Therapy Hepatitis C Virus Organofluorides Treatment Of Cystic Fibrosis HCV Infection
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 195.81
52 Week Low 144.07
Average Volume 1,316,473
200-Day Moving Average 178.9958
50-Day Moving Average 184.1626
20-Day Moving Average 183.082
10-Day Moving Average 180.131
Average True Range 5.036
ADX 18.07
+DI 11.6014
-DI 37.0919
Chandelier Exit (Long, 3 ATRs ) 176.602
Chandelier Exit (Short, 3 ATRs ) 178.788
Upper Bollinger Band 196.9738
Lower Bollinger Band 169.1902
Percent B (%b) -0.02
BandWidth 15.175495
MACD Line -3.405
MACD Signal Line -1.1572
MACD Histogram -2.2478
Fundamentals Value
Market Cap 42.49 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 162.04
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 174.01
Resistance 3 (R3) 173.85 171.85 173.10
Resistance 2 (R2) 171.85 170.46 171.94 172.79
Resistance 1 (R1) 170.19 169.59 171.02 170.35 172.48
Pivot Point 168.19 168.19 168.61 168.28 168.19
Support 1 (S1) 166.53 166.80 167.36 166.69 164.56
Support 2 (S2) 164.53 165.93 164.62 164.25
Support 3 (S3) 162.87 164.53 163.95
Support 4 (S4) 163.03